Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | First-MIND: Phase Ib study of R-CHOP + tafasitamab ± lenalidomide in newly diagnosed DLCBL

Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, briefly comments on the design and results of the First-MIND study (NCT04134936) assessing the safety and tolerability of R-CHOP plus tafasitamab with or without lenalidomide in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

The First-MIND trial, it’s a Phase Ib study that tested the combination of rituximab-CHOP plus tafasitamab or rituximab-CHOP and tafasitamab-lenalidomide. Tafasitamab is the new anti-CD19 engineered antibody and has been added to R-CHOP in first line in diffuse large B cell lymphoma. The main protocols of this study was to prepare the background for the large Phase III randomized Front-MIND study...

The First-MIND trial, it’s a Phase Ib study that tested the combination of rituximab-CHOP plus tafasitamab or rituximab-CHOP and tafasitamab-lenalidomide. Tafasitamab is the new anti-CD19 engineered antibody and has been added to R-CHOP in first line in diffuse large B cell lymphoma. The main protocols of this study was to prepare the background for the large Phase III randomized Front-MIND study. 

In that study, we tested 66 patients, and the patients received R-CHOP and tafasitamab or R-CHOP and tafasitamab-lenalidomide. Overall, the efficacy of the combination is quite good, with more than 80% of complete response rate that were evaluated by PET and progression-free survival that is around 75% at two years. The safety, that was the main purpose of the study, was reasonably good because the main toxicity was myelotoxicity, a little bit higher than R-CHOP alone, but was manageable. So this was done just to prepare the Front-MIND study that is a randomized study.

Read more...

Disclosures

Seagen, Genmab, Incyte, Costellation, Bayer, Regeneron: Consultancy; AbbVie, Incyte, Janssen, Gilead Sciences: Speakers Bureau.